Celsius Holdings Misses Expectations in Q2 2026, Brand Sales Decline
Celsius Holdings announced its financial results for the second quarter of 2026. The company's revenues fell short of analyst expectations, with a notable decline in sales of Celsius-branded products. This was attributed to intensifying competition in the energy drink market and weakening consumer demand.
The company's net sales decreased compared to the same period last year. Sales volumes of Celsius-branded beverages declined across both retail and online channels. Management noted that distributor inventory adjustments and changes in promotional activities contributed to this decline.
Earnings per share (EPS) also came in below expectations. The company's profitability was pressured by increased marketing expenditures and rising raw material costs. Operating margins narrowed compared to the same quarter last year.
Celsius Holdings' management stated that they will focus on new product launches and international expansion to enhance brand awareness and maintain market share in the coming period. However, the company cautioned that a recovery in sales may take time in the short term.
Investors may exert selling pressure on the stock in response to the company's weak performance. Experts suggest that competition in the energy drink sector and shifts in consumer preferences could limit Celsius's growth potential.
This is not investment advice.
📊 CELH — Piyasa Yorumu
▼ down · 65%The headline indicates that the company missed expectations in Q2 2026 and that brand sales declined, which could create negative pressure on the stock. Technical indicators present a neutral outlook, with RSI around 49, MACD just below the signal line, and price above the SMA20 and SMA50. However, the negative fundamental news could increase selling pressure in the short term. The price is likely to test the support zone at $29, but since a strong bearish signal has not yet formed, the decline is expected to be limited. Investors should remain cautious in response to this news flow and monitor support levels.
RSI 14
49.1
MACD
0.17
24h Δ
0.66%
Canlı Grafikler
🔗 İlgili haberler
⭐ 75 · 3 sa önce
Celsius Hisseleri, İkinci Çeyrek Satışları Beklentileri Karşılayamayınca Düştü
⭐ 76 · 14.07
FDA, Celcuity'nin Meme Kanseri İlacına Onay Verdi
⭐ 63 · 14.07
FDA, Celcuity'nin Meme Kanseri İlacına Onay Verdi
⭐ 67 · 17.06
Bernstein, Celsius Holdings İçin 'Endeksin Üzerinde Getiri' Tavsiyesi Verdi
⭐ 67 · 02.06
Celcuity Hisseleri Meme Kanseri Deneyinde Hayal Kırıklığıyla Düştü
⭐ 68 · 12.05
JPMorgan, Celanese hissesi için notunu yükseltti: Değerleme ve nakit akışı vurgusu
🧬 Buna benzer
⭐ 65
Hertz ve FedEx Hisseleri Düşüşte: Kâr Marjı ve Gelir Beklentileri Hayal Kırıklığı Yarattı
⭐ 67
Qualcomm'un 3. Çeyrek Karı %25 Düştü, Maliyetler Arttı
⭐ 72
Mercedes-Benz'in 2026 İkinci Çeyrek Satışları Çin'deki Düşüşle Geriledi
⭐ 75
Cerebras hisseleri, yıl sonu marj tahmininin hayal kırıklığı yaratmasıyla %14 düştü
AI tarafından yeniden derlenmiştir. Yatırım tavsiyesi değildir.